Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Medulloblastoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 10Radiotherapy 10Bevacizumab 6Everolimus 5ribociclib 3Radiation 3Panobinostat 3Dasatinib 3Valproic Acid 2TIC10 compound 2Re-Irradiation 2Nivolumab 2Mebendazole 2Irinotecan 2Gemcitabine 2GDC-0084 2Etoposide 2Erlotinib Hydrochloride 2Diphtheria-Tetanus Vaccine 2Cyclophosphamide 2Cilengitide 2Cetuximab 2vandetanib 1tovorafenib 1temsirolimus 1spartalizumab 1sargramostim 1reolysin 1pembrolizumab 1ovex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diffuse Intrinsic Pontine Glioma × Piperazine × Clear all
NCT02644291 2022-06-23

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
16 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Medulloblastoma, Oligodendroglioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡